Related Experiment Video

Updated: Jul 18, 2026

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

Targeting c-Src kinase enhances tamoxifen's inhibitory effect on cell growth by modulating expression of cell cycle

Maricarmen D Planas-Silva1, Kecia N Hamilton

  • 1Department of Pharmacology, Penn State College of Medicine, 500 University Drive, MCH078, Hershey, PA 17033, USA. mcplanas@psu.edu

Cancer Chemotherapy and Pharmacology
|December 23, 2006
PubMed
Abstract

Insights

Targeting c-Src kinase alongside estrogen receptor (ER) blockade shows promise for ER-positive breast cancer. Combining tamoxifen and c-Src inhibition significantly enhances cell death, suggesting a dual-targeting strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The non-receptor tyrosine kinase c-Src is implicated in cancer development and metastasis.
  • c-Src is proposed to mediate estrogen's role in breast cancer cell cycle progression.

Purpose of the Study:

  • Investigate the interaction between c-Src inhibition and estrogen receptor (ER) function.
  • Evaluate the combined effects of c-Src inhibition and ER blockade on breast cancer cell growth.

Main Methods:

  • Utilized ER-positive, tamoxifen-sensitive MCF-7 breast cancer cells.
  • Employed pharmacological inhibition of c-Src kinase.
  • Assessed effects on cell proliferation, apoptosis, and expression of key target genes.

Main Results:

  • c-Src inhibition blocked estrogen-dependent proliferation and enhanced tamoxifen/estrogen-deprivation effects.
  • Combined tamoxifen and c-Src blockade achieved 95% growth inhibition and induced apoptosis.
  • c-Src inhibition modulated Mcl-1 isoforms and reduced Bad phosphorylation (inactivation) during ER blockade.

Conclusions:

  • c-Src kinase plays a critical role in ER-positive breast cancer cell survival specifically when ER function is blocked.
  • Simultaneous targeting of c-Src and ER presents a potential therapeutic strategy for ER-positive breast cancer.

More Related Videos

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...